Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics

Nakai, Hidekatsu; Matsumura, Noriomi

doi:10.1080/14656566.2023.2295393

Expert Opinion on Pharmacotherapy

2023

DOI: 10.1080/14656566.2023.2295393

|View full text |Cite

Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics

Hidekatsu Nakai,

Noriomi Matsumura

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Advances in systemic treatment for recurrent metastatic cervical cancer

Kang,

Du,

Zeng

et al. 2024

Br J Hosp Med

View full text Add to dashboard Cite

Cervical cancer remains a leading cause of cancer-related mortality among women worldwide, particularly in underdeveloped nations. Despite advances in standard therapies, patients with recurrent metastatic cervical cancer face a poor prognosis and limited treatment options. This study aims to evaluate the efficacy and safety of emerging therapeutic approaches in managing this challenging condition, including immunotherapy, targeted medicines, and chemotherapy. Our review of recent literature and clinical trials highlights the significant progress made in the systematic treatment of metastatic cervical cancer. While each treatment modality has its strengths and limitations, the collective data suggest a trend towards improved patient outcomes with the adoption of these novel therapies. However, the heterogeneity of patient responses underscores the need for personalised treatment strategies. In conclusion, improvements in medical technology and the adoption of tailored treatment approaches have led to promising advancements in the management of recurrent metastatic cervical cancer. To further enhance patient care, there is an urgent need for more extensive clinical trial data and the development of more efficient personalised treatment plans. This study aims to contribute to this effort by comprehensively analysing current therapeutic strategies and identifying areas for future research.

show abstract

Advances in systemic treatment for recurrent metastatic cervical cancer

Kang,

Du,

Zeng

et al. 2024

Br J Hosp Med

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics

Cited by 1 publication

References 76 publications

Advances in systemic treatment for recurrent metastatic cervical cancer

Advances in systemic treatment for recurrent metastatic cervical cancer

Contact Info

Product

Resources

About